Immunological exploration based studies on Strychnos nux-vomica regarding antigen specific immune response
Abstract
In an effort to determine its cytotoxicity as well as antigen specific immune activity of aqueous leaves extract of Strychnos nux-vomica using hepatitis B vaccine containing surface antigen (HBsAg; 20 µg/ml) pertaining to antibody production and scrutinize its proliferative response along with cytokines in lysed human whole blood. For these studies, phytochemical (qualitative) analysis was determined and evaluates the presence of secondary metabolites through high performance thin layer chromatography (HPTLC) and bio-inorganic fingerprinting. In addition, indirect Elisa was performed using HBsAg as coating antigen using variable doses (1-30 mg/ml) of Strychnos nux-vomica. In continuation of these immunological studies, antigen specific immune response along with cytotoxicity was determined through MTT assay in infected human whole blood using HBsAg (20 µg/ml, 50 µl). The results showed that Strychnos nux-vomica showed qualitatively as well as quantitatively determined the presence of secondary metabolites along with bio-inorganic compounds. In addition, Strychnos nux-vomica showed enhancement in anti-HBsAg IgG titre as compared to standard and control but there is sudden decline in proliferation with HBsAg and also showed decline in cytokines (IL-2 and IL-12) level at higher doses as compared to control. Our data suggest that Strychnos nux-vomica may help to raise antibodies against HBsAg but sudden decline in HBsAg proliferative response along with cytokines (IL-2 and IL-12) in infected lysed human whole blood and also showed some cytotoxic effect at higher doses. In other words, Strychnos nux-vomica could be a potent immune enhancer of B cells and inhibitor of T cells against HBsAg.
Downloads
References
2. Gupta A, Khamkar PR, Chaphalkar SR. Applications and uses of active ingredients from medicinal plants. Ind J Nov Drug Del. 2014; 6(2): 106-111.
3. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005; 78: 431-441.
4. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70: 461-477.
5. Negi CS, Nautiyal, S, Dasila L, Rao KS, Maikhuri RK, Ethnomedicinal plant uses in a small tribal community in a part of central Himalaya, India. J Hum Ecol. 2002; 14(1): 23.
6. Gillett NA, Chan C. Applications of immunohistochemistry in the evaluation of immunosuppressive agents. Human Exp Toxicol. 2000; 19(4): 251-254.
7. Patel DK, Patel K, Duraiswamy B. Phytochemical analysis and standardization of Strychnos nux-vomica extract through HPTLC techniques. Asian Pac J Trop Dis. 2012; 2: S56-S60.
8. Kumar A, Sinha BN. Ayurvedic processing of nux vomica: qualitative and quantitative determination of total alkaloidal contents and relative toxicity. Malay J Pharm Sci. 2009; 7: 83-98.
9. Kushwaha RK, Berval R, Sharma A. The therapeutic and toxicological effect of kupilu (Strychnos nux-vomica L.) - a review. Ayushdhara. 2014; 1: 1-4.
10. Bhati R, Singh A, Saharan VA. Strychnos nux-vomica seeds: Pharmacognostical standardization, extraction, and antidiabetic activity. J Ayurveda Integr Med. 2012; 3: 80-84.
11. Galeffi C, Nicoletti M, Messana I. On the alkaloids of Strychnos - XXXI. 15-hydroxystrychnine, a new alkaloid from Strychnos nux-vomica L. Tetrahed. 1979; 35: 2545-2549.
12. Cai BC, Wang TS, Kurokawa M. Cytotoxicities of alkaloids from processed and unprocessed seeds of Strychnos nux-vomica. Acta Pharmacol Sin. 1998; 19: 425-428.
13. Makhija IK, Khamar D. Anti-snake venom properties of medicinal plants. Pharmacia Lettre. 2010; 2(5): 399-411.
14. Frederich M, Choi YH, Angenot L. Metabolomic analysis of Strychnos nux-vomica, Strychnos icaja and Strychnos ignatii extracts by 1H nuclear magnetic resonance spectrometry and multivariate analysis techniques. Phytochem. 2004; 65: 1993-2001.
15. Xu YY, Si DY, Liu CX. Research on bioresponse of active compounds of Strychnos nux-vomica L. Asian J Pharmacokin Pharmacodyn. 2009; 9: 179-201.
16. Zhang JY, Li N, Hu K. Chemical constituents from processed seeds of Strychnos nux-vomica. J Chin Pharm Sci. 2012; 21: 187-191.
17. Shi Y, Liu Y, Ma S. Four new minor alkaloids from the seeds of Strychnos nux-vomica. Tetrahedron Lett. 2014; 55: 6538-6542.
18. Yang GM, Tu X, Liu LJ. Two new bisindole alkaloids from the seeds of Strychnos nux-vomica. Fitoterap. 2010; 81: 932-936.
19. Zhao N, Li L, Liu J. New alkaloids from the seeds of Strychnos nux-vomica. Tetrahed. 2012; 68: 3288-3294.
20. Fu Y, Zhang Y, He H. Strynuxlines A and B, alkaloids with an unprecedented carbon skeleton from Strychnos nux-vomica. J Nat Prod. 2012; 75: 1987-1990.
21. Zhang X, Xu Q, Xiao H. Iridoid glucosides from Strychnos nux-vomica. Phytochem. 2003; 64: 1341-1344.
22. Bisset NG, Choudhury AK. Alkaloids and iridoids from Strychnos nux-vomica fruits. Phytochem. 1974; 13: 265-269.
23. Bisset NG, Choudhury AK, Houghton PJ. Phenolic glycosides from the fruit of Strychnos nux-vomica. Phytochem. 1989; 28: 1553-1554.
24. Thambi M, Cherian T. Phytochemical investigation of the bark of Strychnos nux-vomica and its antimicrobial properties. Pharma Innovation J. 2015; 4: 70-72.
25. Biala RG, Tits M, Penelle J. Strychnochrysine, a new bisindole alkaloid from the roots of Strychnos nux-vomica. J Nat Prod. 1998; 61: 139-141.
26. Gupta A, Chaphalkar SR. Immunoadjuvant potential of Azadirachta indica against rabies, hepatitis and DPT vaccine antigen. Int J Med Pharm Sci. 2015; 5(7): 1-5.
27. Gupta A, Chaphalkar SR. Anti-inflammatory activity of flavonoids from medicinal plants against hepatitis B vaccine antigen on human peripheral blood mononuclear cells. Asian J Pharm Clin Res. 2015; 3(1): 728-732.
28. Gupta A, Prakash J, Chaphalkar SR. Aristolochia bracteolate: Potent enhancer of B cells and inhibits T cell population against specific protein antigen. Eur J Pharm Med Res. 2016; 3(10): 250-254.
29. Gupta A, Khajuria A, Singh J, Singh S, Suri KA, Qazi GN. Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice. Int Immunopharm. 2011; 11(8): 968-975.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
